Effects and Safety of Linezolid vs. Vancomycin for the Treatment of Patients with MRSA：Meta Analysis of Randomized Controlled Trials
LI Ying1，2，TANG Hui-lin1，HU Yong-fang1*，PENG Fang-chen2
Author information+
1.Department of Pharmacy，Peking University Third Hospital，Beijing 100191， China；2.Department of Clinical Pharmacy， Shanxi Provinical People's Hospital，Taiyuan，030012， China
OBJECTIVE To compare the effects and safety of linezolid and vancomycin for the treatment of patients with MRSA. METHODS Cochrane library，MEDLINE，Embase，PUBMED，CNKI，VIP database，Wanfang database and paper manual of related conferences were searched. Then Meta analysis were performed by RevMan 5.0. RESULTS Twelve studies were included （n=3 405）. The analysis indicated that there were significant differences between linezolid and vancomycin in survival rate［OR=1.71，95%CI （1.23，2.37），P＝0.002］，especially for MRSA pneumonia［OR=1.94，95%CI （1.34，2.81），P=0.000 4］，clinical cure rate［OR＝1.57，95%CI （1.08，2.28），P<0.05］ and microbiological cure rate［OR＝2.03，95%CI （1.12，3.66），P<0.05］，especially for the SSTI or SSI. There was no significant difference between the 2 groups in the adverse event rate［OR＝1.10，95%CI（0.92，1.31），P﹥0.05］. CONCLUSION With superior effects，similar safety，better tolerability and less toxicity，linezolid may be preferred for the patients with critical illness and renal dysfunction.
LI Ying;TNG Hui-lin;HU Yong-fng;PENG Fng-chen.
Effects and Safety of Linezolid vs. Vancomycin for the Treatment of Patients with MRSA：Meta Analysis of Randomized Controlled Trials[J]. Chinese Pharmaceutical Journal, 2011, 46(13): 1041-1045
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ ZHU D M，WANG F， ZHANG Y Y. Surveillance of bacterial resistance in hospitals of Shanghai during 2005［J］. Chin J Infect Chemother （中国感染与化疗杂志），2006，6 （6）： 371-378. ［2］ WANG H，SUN H L CHEN M J，et al. Antimicrobial resistance surveillance of gram-positive cocci isolated from 5 teaching hospitals in China in 2005［J］. Chin J Lab Med （中华检验医学杂志），2006，29 （10） ：873-878. ［3］ FALAGAS M E，KASTORIS A C，KAPASKELIS A M. Fosfomycin for the treatment of multidrug-resistant，including extended-spectrum beta-lactamase producing，Enterobacteriaceae infections： a systematic review［J］. Lancet Infect Dis，2010，10（1）： 43-50. ［4］ SHORR A F，KUNKEL M J， KOLLEF M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia： pooled analysis of randomized studies［J］. J Antimicro Chem，2005，56（5）： 923-929. ［5］ STEVENS D L，HERR D，LAMPIRIS H，et al. Linezolid versus Vancomycin for the treatment of methicillin-resistant staphylococcus aureus infection［J］. Clin Infect Dis，2002，34（11）： 1481-1490. ［6］ RUBINSTEIN E，CAMMARATA S，OLIPHANT T，et al. Linezolid （PNU-100766） versus Vancomycin in the treatment of hospitalized patients with nosocomial pneumonia： A randomized，double-blind，multicenter Study［J］. Clin Infect Dis，2001，32（3）： 402-412. ［7］ WEIGELT J，KAAFARANI H，ITANI K，et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infection［J］. Am J Surg，2004，188（6）： 760-766. ［8］ WEIGELT J，ITANI K，STEVENS D，et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissu infections［J］. Antimicrob Agents Chemother，2005，49（6）：2260-2266. ［9］ KAPLAN S L，AFGHANI B，LOPEZ P，et al. Linezolid for the treatment of methicillin-resistant staphylococcus aureus infections in children［J］. Pediatr Infecy Dis J，2003，22 （9 suppl）： 178-185. ［10］ KOHNO S，YAMAGUCHI K，AIKAWA N，et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan［J］. J Antimicrob Chemother，2007，60（6）： 1361-1369. ［11］ KOLLEF M H，RELLO J，CAMMARATA S K，et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia： retrospective analysis of two double-blind studies comparing linezolid with vancomycin［J］. Intensive Care Med，2004，30（3）：338-394. ［12］ WUNDERINK R G，CAMMARATA S K，OLIPHANT T H，et al. Continuation of a randomized，double- blind，multicenter study of linezolid versue vancomycin in the treatment of patients with nosocomial pneumonia［J］. Clin Ther， 2003，25（3）：980-992. ［13］ WUNDERINK R G，RELLO J，CAMMARATA S K，et al. Linezolid vs Vancomycin： Analysis of two double-bline studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia［J］. Chest，2003，124（5）：1789-1797. ［14］ SHARP J N，SHIVELY E H，POLK H C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated，lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus［J］. Am J Surg，2005，189（4）： 425-428. ［15］ FALAGAS M E，SIEMPOS I，VARDAKAS K Z. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections： meta-analysis of randomized controlled trials［J］. Lancet Infect Dis，2008，8（1）： 53-66.
PDF(2522 KB)
